Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
How to invest
How to invest like Warren Buffett with ASX shares in 2025
Dividend Investing
21 ASX shares going ex-dividend next week
How to invest
No savings at 50? I'd buy ASX 200 shares and aim to retire rich
Broker Notes
Brokers name 3 ASX shares to buy today
Share Gainers
Here are the top 10 ASX 200 shares today
How to invest
Here's how $15,000 in an ASX share portfolio could grow into $200,000
Share Gainers
Here are the top 10 ASX 200 shares today
Healthcare Shares
The Cochlear share price hit a 52-week low last week, is it time to buy?
Share Fallers
Why AMP, Civmec, Cochlear, and LGI shares are falling today
Earnings Results
Cochlear share price sinks 10% on half-year result disappointment
Share Market News
5 things to watch on the ASX 200 on Friday
Healthcare Shares
Which ASX 200 healthcare share will pay the best dividend yield in 2025?
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
